EUROPEAN COMMISSION DIRECTORATE-GENERAL REGIONAL POLICY Policy development Conception, forward studies, impact assessment

AGENDA Structured Dialogue with associations representing regional, local, urban and other public authorities, economic and social partners, and civil society bodies

EU Cohesion Policy 2014-2020 – State of Play 14 SEPTEMBER 2012 Albert Borschette Conference Centre 36 Rue Froissart B-1040 Brussels ROOM AB-4B

WELCOME COFFEE & REGISTRATION (9:30 to 10am) MORNING SESSION OPENING SESSION: THE FUTURE OF THE COHESION POLICY AND THE COMMISSION LEGISLATIVE PROPOSAL 2014-2020 - STATE OF PLAY (10:00 to 10:45) Welcome and introductory speech: Walter DEFFAA, European Commission, Director General, Directorate-General for Regional Policy State of play of the negotiations: Nicholas MARTYN, European Commission, Deputy Director General, Development, Coordination and Communication of Cohesion Policy, Directorate-General for Regional Policy QUESTIONS AND ANSWERS PANEL 1: MULTILEVEL GOVERNANCE AND PARTNERSHIP - THE EUROPEAN CODE OF CONDUCT (10:45 to 12:45) Chair: Peter BERKOWITZ, European Commission, Head of Unit Conception, forward studies, impact assessment Panel discussion with civil society bodies Manuela GELENG, European Commission, Head of Unit, ESF Legislation and Policy, Financial Engineering, Directorate-General for Employment, Social Affairs and Inclusion István FARKAS, International Co-ordinator, SFTeam for sustainable future Peter TORKLER, Structural Funds Coordinator, WWF Anelia STEFANOVA, Campaigns Director, CEE Bankwatch Fintan FARRELL, Director of the European Anti-poverty Network, EAPN OPEN DISCUSSION

Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11. Office: CSM1 09/030. Telephone: direct line (32-2) 299.46.13. Fax: (32-2) 296.62.35. http://ec.europa.eu/regional_policy/ E-mail: [email protected]

LUNCH BREAK (12:45 to 14:15)

AFTERNOON SESSION PANEL 2: SPECIFIC PROVISIONS ON THE TREATMENT OF PARTICULAR TERRITORIAL FEATURES (14:15 to 15:45) Chair: Peter BERKOWITZ, European Commission, Head of Unit Conception, forward studies, impact assessment Panel discussion with associations representing regional, local, urban and other public authorities Wladyslaw PISKORZ, European Commission, Head of Unit Urban development and territorial cohesion, Directorate-General for Regional Policy Dorthe NIELSEN, Senior Policy Adviser, EUROCITIES Angelika POTH-MÖGELE, Director of Policy, Council of European Municipalities and Regions, CEMR Pascal GOERGEN, Secretary General, Assembly of European Regions, AER Nicolas BROOKES, Director for Regional and Cohesion Policy, CPMR OPEN DISCUSSION COFFEE BREAK (15:45 to 16:00)

PANEL 3: THE COMMON STRATEGIC FRAMEWORK 2014- 2020 (16:00 to 17:30) Chair: Peter BERKOWITZ, European Commission, Head of Unit Conception, forward studies, impact assessment Panel discussion with economic and social partners Ann-Kerstin MYLEUS, European Commission, Deputy Head of Unit Conception, forward studies, impact assessment Luigi MARTIGNETTI, Secretary General of the European Network of Cities and Regions for the Social Economy, REVES Claude DENAGTERGAL, Advisor, European Trade Union Confederation, ETUC Joana VALENTE, Adviser, BUSINESSEUROPE Hubert DELORME, Senior Counsellor Regional Policy and Structural Funds, European Association of Craft, Small and Medium-sized enterprises, UEAPME David ANCIAUX, Project manager, The European Centre of Employers and Enterprises Providing Public Services, CEEP OPEN DISCUSSION CLOSING REMARKS (17:30 to 17:45) Peter BERKOWITZ, European Commission, Head of Unit Conception, forward studies, impact assessment

2

AGENDA EU Cohesion Policy 2014-2020 - European Commission

Sep 14, 2012 - General, Development, Coordination and Communication of ... István FARKAS, International Co-ordinator, SFTeam for sustainable future.

25KB Sizes 8 Downloads 250 Views

Recommend Documents

AGENDA EU Cohesion Policy 2014-2020 - European Commission
Sep 14, 2012 - WELCOME COFFEE & REGISTRATION (9:30 to 10am) ... Welcome and introductory speech: Walter DEFFAA, European Commission, Director ...

EU ACC3 - European Commission - Europa EU
As a shipper, freight forwarder, screening facility, ground handler or postal operator you may handle cargo or mail relevant to this programme. Is your company.

The CETA Agreement - European Commission - Europa EU
Regarding wine and spirits CETA also: • abolishes the Canadian requirement to blend imported bulk spirits with local spirits before bottling – a requirement that made it impossible for EU makers of products classified as Geographical. Indications

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...

Agenda - European Medicines Agency - Europa EU
Feb 9, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. •. Product

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri

Agenda - European Medicines Agency - Europa EU
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina Schüßler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g

Agenda - European Medicines Agency - Europa EU
Dec 7, 2016 - publication of clinical data (Policy 0070) and revisions to the guidance to industry – Industry Associations Webinar. 9 December 2016, 10:00 to ...

Agenda - European Medicines Agency - Europa EU
Sep 19, 2017 - 14:00-14:05. 2. Data integrity – early signal detection. - data patterns/trends in data ... 16:20-17:00. 5. Inspections of Ligand Binding Assays (in.

Agenda - European Medicines Agency - Europa EU
Nov 7, 2017 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union. Telephone ...... Visualisation of choline metabolism in malignant neoplasms ..... A paediatric investigation plan (PIP) is a dev

Agenda - European Medicines Agency - Europa EU
Jan 23, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be

Agenda - European Medicines Agency - Europa EU
Oct 24, 2017 - Application of Article 8(2) of the Orphan Regulation ..... propoxy)-phenyl]-methanone, EMA/OD/187/14 Herpes simplex type 1 virus containing.

Agenda - European Medicines Agency - Europa EU
Jun 14, 2016 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom ... EMA initiatives to support and accelerate early access. 10:00 2.1 ...

Agenda - European Medicines Agency - Europa EU
6 days ago - EMA/OD/103/14 Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment, EMA/OD/175/14 Allogeneic ...

Agenda - European Medicines Agency - Europa EU
o Pilot to test draft model ... Endorsement of Enpr-EMA membership criteria Mark Turner/Irmgard. Eichler ... Endorsement of newly received applications.

Agenda - European Medicines Agency - Europa EU
Jan 23, 2018 - HCP/patient cross-sectional survey and retrospective chart review Post Authorisation. Safety Study to evaluate the effectiveness of the Patient Alert Card for both IV and SC abatacept in a sample of EU countries. Positive Opinion adopt

Agenda - European Medicines Agency - Europa EU
Jan 8, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. ... EU referral procedures for safety reasons: urgent EU procedures 13. 2.1. ...... clinical data from st

Agenda - European Medicines Agency - Europa EU
Nov 3, 2016 - Scope: 'Optimising the development of ATMPs to meet patient needs' ... the CAT would like to discuss with company representatives in person.

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - EMEA/V/C/002526. Rapp: G. J. Schefferlie. For adoption: CVMP assessment report on the targeted. PSUR for the period 11.02.14-31.12.16 ...

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - under Article 107i of Directive 2001/83/EC, based on pharmacovigilance data. Action: For adoption of ..... manufacturing process; and 3) removal of the following missing information: special patient groups. Action: For .... analysis of